article · Minerva Urology and Nephrology
The novel combination therapies of tadalafil 5mg with solifenacin or mirabegron are more effective in reducing OAB symptoms and improving urodynamic parameters compared to single-agent therapies and placebo. These findings suggest that combination therapy is alternative pathway which can enhance outcomes for female patients with OAB. Further research is warranted to validate these results and explore long-term efficacy and safety.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.23736/s2724-6051.25.06129-4
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
